Drug Profile
Anti MUC 1 chimeric antigen receptor T cell therapy - Innovative Cellular Therapeutics
Alternative Names: Anti-MUC 1 CART cell therapy; MUC-1 CAR T cellLatest Information Update: 28 Jan 2021
Price :
$50
*
At a glance
- Originator Innovative Cellular Therapeutics
- Class CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Breast cancer; Lung cancer; Pancreatic cancer
Most Recent Events
- 28 Jan 2021 No recent reports of development identified for phase-I development in Breast-cancer(Metastatic disease, Second-line therapy or greater) in China (Parenteral)
- 28 Jan 2021 No recent reports of development identified for phase-I development in Lung-cancer(Recurrent, Refractory metastatic disease, Second-line therapy or greater) in China (Parenteral)
- 28 Jan 2021 No recent reports of development identified for phase-I development in Pancreatic-cancer(Late-stage disease) in China (Parenteral)